DRUG DISCOVERY FOR PARASITIC DISEASES AND BACTERIAL DISEASES POWERED BY TECHNOLOGY ENABLED BY PHARMACOLOGY INFORMED BY CLINICAL SCIENCE
Main Article Content
Keywords
Drug, parasitic, bacterial, diseases, computational, experimental, clinical
Abstract
This work focuses on the drug development for parasitic and bacterial diseases using a combination of computational, experimental, and clinical methods for drug identification. It employs molecular docking, high through put screening (HTS), pharmacological activity and CRISPR-Cas9 assay for determining the potential therapeutic value of the tested compounds, their toxicity and demonstrating that the targets are indeed valid. In order to gain insights into the current therapy and advanced technologies in drug development, a literature search was also carried out. The authors found Compound C1 to be the most potent and selective hit that bind strongly, possesses good biological activity, low cytotoxicity and good gene target profile. The integration of different Endocrine techniques enabled the identification and prioritization of drug candidates; this study presents a sound framework upon which further clinical trials may be based. This research highlights the need to work in a team when conducting drug discovery and development using the complementary approaches that are discussed in this investigation to develop target specific drugs for parasitic and bacterial diseases.
References
1. Amin, N. M., et al. (2023). "Repurposing drugs for parasitic diseases: Opportunities and challenges." Parasitology International, 89, 102457.
2. Brown, C. M., et al. (2023). "High-throughput screening of natural product libraries for the discovery of new treatments for neglected tropical diseases." International Journal of Antimicrobial Agents, 62(4), 105596.
3. Brown, K. A., et al. (2022). Clinical trials in drug discovery for bacterial infections: Insights from recent trials. The Lancet Infectious Diseases, 22(5), 563-572.
4. Choi, Y. J., et al. (2020). "Pharmacological considerations in drug development for bacterial infections." Frontiers in Pharmacology, 11, 529.
5. Gupta, A., et al. (2022). "Machine learning and AI in drug repurposing for infectious diseases." Journal of Pharmaceutical Sciences, 111(5), 1741-1753.
6. Jiang, F., et al. (2020). CRISPR-Cas9-based gene editing for the treatment of bacterial infections. Trends in Microbiology, 28(10), 866-877.
7. Jiang, S., et al. (2020). "Artificial intelligence for accelerating the identification of drug-target interactions in bacterial pathogens." Nature Communications, 11, 2095.
8. Lee, J. W., et al. (2022). "CRISPR-Cas9 as a tool for identifying novel therapeutic targets for parasitic diseases." Nature Microbiology, 7(9), 1283-1291.
9. Lee, K. W., et al. (2023). Targeting antibiotic resistance: Innovations in drug design and precision medicine. Nature Microbiology, 8(1), 1-9.
10. Liu, J., et al. (2020). "Structural biology in drug discovery: Applications in bacterial drug development." Nature Reviews Drug Discovery, 19(7), 446-460.
11. Liu, X., et al. (2021). High-throughput screening for identifying new antimicrobial agents against resistant pathogens. Frontiers in Pharmacology, 12.
12. Martin, L., et al. (2022). "Global collaborations in antimicrobial research and development." Lancet Infectious Diseases, 22(10), 1337-1346.
13. Patel, R., et al. (2024). "Genetic insights into antimicrobial resistance and its implications for precision medicine." Clinical Infectious Diseases, 77(3), 526-535.
14. Ravindran, J., et al. (2021). "AI applications in drug discovery for parasitic diseases." Computational Biology and Chemistry, 87, 107247.
15. Ravi, S., et al. (2023). "Clinical trials in drug discovery: Optimizing phase II and III trials for antimicrobial agents." Journal of Clinical Trials, 17(4), 150-165.
16. Stojanovic, J., et al. (2021). "Personalized medicine in antimicrobial therapy: The future of treating infections." Frontiers in Microbiology, 12, 752834.
17. Singh, N., et al. (2021). HTS and drug repurposing in the discovery of treatments for neglected tropical diseases. Antimicrobial Agents and Chemotherapy, 65(3), 2312-2323.
18. Smith, J., et al. (2024). Phase 3 clinical trials in antimicrobial drug discovery: A global perspective. Clinical Microbiology Reviews, 37(1).
19. Vajpayee, M., et al. (2023). "New strategies in the treatment of drug-resistant tuberculosis." Journal of Clinical Microbiology, 61(1), e00821-22.
20. Yang, Y., et al. (2022). Rapid development of therapeutics in response to infectious disease pandemics: Lessons learned from COVID-19. Science Translational Medicine, 14(664), eabm5282.
21. Zhang, L., et al. (2022). "Advancements in pharmacokinetics for tuberculosis therapy optimization." Journal of Antimicrobial Chemotherapy, 77(2), 510-520.
22. Zhao, Y., et al. (2021). "Gene editing in malaria parasites: The promise and challenges." Trends in Parasitology, 37(5), 362-374.
23. Zhou, W., et al. (2023). AI-driven drug discovery in parasitic diseases: Current applications and future directions. Nature Reviews Drug Discovery.
2. Brown, C. M., et al. (2023). "High-throughput screening of natural product libraries for the discovery of new treatments for neglected tropical diseases." International Journal of Antimicrobial Agents, 62(4), 105596.
3. Brown, K. A., et al. (2022). Clinical trials in drug discovery for bacterial infections: Insights from recent trials. The Lancet Infectious Diseases, 22(5), 563-572.
4. Choi, Y. J., et al. (2020). "Pharmacological considerations in drug development for bacterial infections." Frontiers in Pharmacology, 11, 529.
5. Gupta, A., et al. (2022). "Machine learning and AI in drug repurposing for infectious diseases." Journal of Pharmaceutical Sciences, 111(5), 1741-1753.
6. Jiang, F., et al. (2020). CRISPR-Cas9-based gene editing for the treatment of bacterial infections. Trends in Microbiology, 28(10), 866-877.
7. Jiang, S., et al. (2020). "Artificial intelligence for accelerating the identification of drug-target interactions in bacterial pathogens." Nature Communications, 11, 2095.
8. Lee, J. W., et al. (2022). "CRISPR-Cas9 as a tool for identifying novel therapeutic targets for parasitic diseases." Nature Microbiology, 7(9), 1283-1291.
9. Lee, K. W., et al. (2023). Targeting antibiotic resistance: Innovations in drug design and precision medicine. Nature Microbiology, 8(1), 1-9.
10. Liu, J., et al. (2020). "Structural biology in drug discovery: Applications in bacterial drug development." Nature Reviews Drug Discovery, 19(7), 446-460.
11. Liu, X., et al. (2021). High-throughput screening for identifying new antimicrobial agents against resistant pathogens. Frontiers in Pharmacology, 12.
12. Martin, L., et al. (2022). "Global collaborations in antimicrobial research and development." Lancet Infectious Diseases, 22(10), 1337-1346.
13. Patel, R., et al. (2024). "Genetic insights into antimicrobial resistance and its implications for precision medicine." Clinical Infectious Diseases, 77(3), 526-535.
14. Ravindran, J., et al. (2021). "AI applications in drug discovery for parasitic diseases." Computational Biology and Chemistry, 87, 107247.
15. Ravi, S., et al. (2023). "Clinical trials in drug discovery: Optimizing phase II and III trials for antimicrobial agents." Journal of Clinical Trials, 17(4), 150-165.
16. Stojanovic, J., et al. (2021). "Personalized medicine in antimicrobial therapy: The future of treating infections." Frontiers in Microbiology, 12, 752834.
17. Singh, N., et al. (2021). HTS and drug repurposing in the discovery of treatments for neglected tropical diseases. Antimicrobial Agents and Chemotherapy, 65(3), 2312-2323.
18. Smith, J., et al. (2024). Phase 3 clinical trials in antimicrobial drug discovery: A global perspective. Clinical Microbiology Reviews, 37(1).
19. Vajpayee, M., et al. (2023). "New strategies in the treatment of drug-resistant tuberculosis." Journal of Clinical Microbiology, 61(1), e00821-22.
20. Yang, Y., et al. (2022). Rapid development of therapeutics in response to infectious disease pandemics: Lessons learned from COVID-19. Science Translational Medicine, 14(664), eabm5282.
21. Zhang, L., et al. (2022). "Advancements in pharmacokinetics for tuberculosis therapy optimization." Journal of Antimicrobial Chemotherapy, 77(2), 510-520.
22. Zhao, Y., et al. (2021). "Gene editing in malaria parasites: The promise and challenges." Trends in Parasitology, 37(5), 362-374.
23. Zhou, W., et al. (2023). AI-driven drug discovery in parasitic diseases: Current applications and future directions. Nature Reviews Drug Discovery.
Article Sidebar
Published
Sep 04, 2024
Article Details
How to Cite
Khulood Fahad Alabbosh, Sakina Ibrahim Ali Abonaib, Naglaa M Shalaby, Musa Elhag, Sozan M. Abdelkhalig, Hiba Mahgoub Ali Osman, Abdulmajeed Lafi Alruwaili, Fawaz Saror Alrasheedi, & Amany M. Khalifa. (2024). DRUG DISCOVERY FOR PARASITIC DISEASES AND BACTERIAL DISEASES POWERED BY TECHNOLOGY ENABLED BY PHARMACOLOGY INFORMED BY CLINICAL SCIENCE. Journal of Population Therapeutics and Clinical Pharmacology, 31(9), 3441-3453. https://doi.org/10.53555/kwth6c74
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Khulood Fahad Alabbosh
Department of Biology, College of Science, University of Hail, Hail 2440, Saudi Arabia.
Sakina Ibrahim Ali Abonaib
Department of Physics , Faculty of Science and Arts in Almakhwah, University of Albaha.
Naglaa M Shalaby
Department of Microbiology, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia 91431. Department of Medical Parasitology, Faculty of Medicine, Mansoura University, Mansoura City-35516, Egypt.
Musa Elhag
Faculty of Applied Medical Science, Northern border University, KSA
Sozan M. Abdelkhalig
Department of Basic Medical Sciences, College of Medicine, AlMaarefa University, Diriyah 13713, Riyadh, Saudi Arabia
Hiba Mahgoub Ali Osman
Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha,P.O. Box 551, Bisha 61922, Saudi Arabia
Abdulmajeed Lafi Alruwaili
Laboratory specialist, Northern Border Regional LaboratoryFawaz Saror Alrasheedi
Preventive Medicine and Public Health Consultant, Head of Surveillance Dept at Vector Control Center Alqassim Health Cluster,KSAAmany M. Khalifa
Pathology department, Faculty of Medicine ,University of Ha’il, KSA.
How to Cite
Khulood Fahad Alabbosh, Sakina Ibrahim Ali Abonaib, Naglaa M Shalaby, Musa Elhag, Sozan M. Abdelkhalig, Hiba Mahgoub Ali Osman, Abdulmajeed Lafi Alruwaili, Fawaz Saror Alrasheedi, & Amany M. Khalifa. (2024). DRUG DISCOVERY FOR PARASITIC DISEASES AND BACTERIAL DISEASES POWERED BY TECHNOLOGY ENABLED BY PHARMACOLOGY INFORMED BY CLINICAL SCIENCE. Journal of Population Therapeutics and Clinical Pharmacology, 31(9), 3441-3453. https://doi.org/10.53555/kwth6c74